TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04150068
Drug: Failing ARV Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Failing antiretroviral (ARV) regimen defined by the lack of efficacy. Any combination of approved and unapproved agents that could potentially be part of the failing regimen.
Study: NCT04150068
Drug: Optimized Background Regimen (OBR)
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized background regimen as prescribed by the Investigator
Study: NCT01853696
Drug: prednisolone acetate 1%
Normalized name: PREDNISOLONE ACETATE 1% SUSP,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04521114
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously every week for 13 weeks.
Study: NCT00913224
Drug: Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)
Normalized name: diclofenac sodium 50 MG
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00772187
Drug: intrathecal analgesia (morphine)
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1-0.5 mg of morphine
Study: NCT00772187
Drug: general anesthesia (fentanyl)
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: general anesthesia alone
Study: NCT00438256
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally starting on day one of radiation therapy for 2 weeks
Study: NCT01846468
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules
Study: NCT00798018
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air injected into the cuff to seal the space between the trachea and the tube at minimal volume
Study: NCT00798018
Drug: N.S
Normalized name: INTRAPERITONEAL ADMIN.SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Normal saline injected into the cuff to seal the space between the trachea and the tube at minimal volume
Study: NCT00354042
Drug: GW597901X
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01709071
Drug: Middle dose Sabin-IPV
Normalized name: Juniperus sabina leaf
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01709071
Drug: Middle dose adjuvanted Sabin-IPV
Normalized name: Juniperus sabina leaf
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00771979
Drug: AZD0530
Approvals — FDA: no, EMA: no, PMDA: no
Description: of both the Phase II and Phase III AZD0530 125mg tablet variants (A and B) in a random order.
Study: NCT02563522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care plus placebo
Study: NCT00771979
Drug: AZD0530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part II: Single doses of AZD0530 125mg oral solution and 2 out of 4 125mg tablet variants (C, D, E and F) in a random order.
Study: NCT02294461
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01065714
Drug: Eucerin Lotion
Normalized name: EUCERIN LOTION,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each morning and evening, gently wash the area with warm water and pat dry with a soft towel. Once dry, place a small amount of Eucerin lotion to the target area on either the left or right side of the body as instructed. (Do not use Eucerin and Hydrogel vehicle on the same side of the body.)
Study: NCT00003934
Drug: tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00003934
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00003934
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02738229
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00612716
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 60 mg/kg/day on days -7 and -6. For patients not eligible for total body irradiation: cytoxan 50 mg/kg intravenously (IV) on days -5 through -2.
Study: NCT00002761
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00371696
Drug: diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00323024
Drug: NX1011
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02943785
Drug: VKA-based Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosed at International Normalized Ratio (INR) levels, which is a test of how long it takes for blood to clot. Standard of Care treatment in the country location (with anti-platelet therapy pre-declared at randomization if prescribed).
Study: NCT03124355
Drug: placebo sugar pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo single oral dose
Study: NCT00214734
Drug: rAHF-PFM
Normalized name: Advate rAHF-PFM
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02415335
Drug: Isotonic NaCl
Normalized name: ISOTON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administration minimum of 30 minutes preoperatively
Study: NCT00905268
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
Study: NCT01743118
Drug: SPS4251 Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)
Study: NCT01743118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)
Study: NCT01743118
Drug: Daivonex® ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments).
Study: NCT01207115
Drug: ABT-652
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-652 capsules - twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm
Study: NCT01207115
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules - twice daily for 8 weeks
Study: NCT01207115
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen capsules - twice daily for 8 weeks
Study: NCT00960284
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT00960284
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01020487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules taken with water
Study: NCT02801526
Drug: CKD-330 16/5mg - A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00586508
Drug: Non-enzyme inducing antiepileptic drugs (NEIAED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00518310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00518310
Drug: AZAPRED
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose of prednisone will be 0.5 mg/kg/day for 4 weeks, then 0.25 mg/kg/day for 8 weeks. The dose will continue to decrease at a rate of 5 to 10 mg per week, to a dose of 0.25 or 0.125 mg/kg/day. Azathioprine will be given at a dose of 2-3 mg/kg/day (max 100 mg).
Study: NCT02431806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched over-encapsulated placebo capsules administered orally on Day 1 to Week 8.
Study: NCT02431806
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Over-encapsulated fluoxetine tablets administered orally on Day 1 to Week 8.
Study: NCT01093690
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus placebo 20 mg oral four times a day on day 2-5
Study: NCT01926197
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin 400 mg/m² IV over 2 hours on Day 1 of a 14-day cycle.
Study: NCT01926197
Drug: 5FU
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5FU 2,400 mg/m² IV over 46 to 48 hours starting on Day 1 of a 14-day cycle.
Study: NCT00889187
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00512473
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 % NaCl
Study: NCT01686256
Drug: Tc 99m EC20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive 1 mg of folic acid injected 1-3 minutes prior to administration of Technetium Tc 99m EC20.
Study: NCT03205345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT00234832
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet QD plus country-specific standard care for weight management (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
Study: NCT01234675
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg twice daily
Study: NCT00525642
Drug: Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 six cycles
Study: NCT00525642
Drug: Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 100mg/m2 four cycles; Doxorubicin 60mg/m2 or epirubicin 75mg/m2 ,cyclophosphamide 600mg/m2) four cycles
Study: NCT04006652
Drug: ApoGraft
Approvals — FDA: no, EMA: no, PMDA: no
Description: ApoGraft is a cell based product, manufactured with mobilized peripheral blood.
Study: NCT03017131
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01799993
Drug: Amikacin Inhalation Solution (BAY41-6551)
Normalized name: amikacin Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of aerosolized amikacin every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
Study: NCT01799993
Drug: Aerosolized Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized placebo every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
Study: NCT01333956
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo drug with no active ingredients per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Study: NCT00410462
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02655419
Drug: ATM-AVI
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cohort 1:~(Creatinine clearance \> 50 mL/min)6500mg ATM/1777mg AVI on day 1 followed by total daily dose of 6000mg ATM/1640mg AVI~Cohorts 2 and 3:~(Creatinine clearance \> 50 mL/min) As above, or: 6500 mg ATM/2167 mg on Day 1 followed by a total daily dose of 6000 mg ATM/2000 m AVI~(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1162 mg AVI on Day 1 followed by total daily dose 3000 mg ATM/820 mg AVI, or:~4250 mg ATM/1417 mg AVI on Day 1 followed by total daily dose 3000 mg ATM/1000 mg AVI
Study: NCT03149887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert solution created to appear as liposomal bupivacaine (Exparel) for injection
Study: NCT00501111
Drug: AZD3480
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 oral doses
Study: NCT02620384
Drug: Experimental: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first placebo dose is given within six hours of admininstration of first dose of intravenous diuretic. The second placebo dose is given at 24-hours after the first dose.
Study: NCT01657071
Drug: YH14659
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH14659 capsule by oral
Study: NCT03838406
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX :~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + Fluorouracil (5-FU) 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.~CAPOX:~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days.
Study: NCT01900431
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: Tablet or Capsule or Suspension; Route of administration: Orally or intravenously or intramuscular
Study: NCT01900431
Drug: Folic/folinic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
Study: NCT01704001
Drug: ART-123
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 380 U/kg/day or 130 U/kg/day(Subjects with severe renal impairment) for 6 days
Study: NCT03403621
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active ingredient. Approximately 1.8 mL single dose delivered as topical silicone compounding base only.
Study: NCT03441282
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After the patient is attached to an ASA non-invasive monitor, a dose (2mcg/kg) of Fentanyl will be administered.~Groups compared would include patients experiencing respiratory depression vs those not experiencing respiratory depression after fentanyl administration. Their samples would be evaluated for any differences in genetic make-up concerning selected, known sequences affecting opioid-induced analgesia.
Study: NCT00932386
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline infusing
Study: NCT03239171
Drug: Life information rehabilitation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Study: NCT01828476
Drug: ABT-263
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
Study: NCT01229813
Drug: low dose capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine 500 mg twice daily
Study: NCT00727987
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 24.
Study: NCT00727987
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 mg/week to 8 mg/week taken orally (by mouth) from at least 4 weeks before the initial investigational treatment to the completion of assessment at Week 52.
Study: NCT01196936
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet daily
Study: NCT00711776
Drug: Current formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current formulation of Aciclovir Cream 5% in Japan
Study: NCT04950790
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Give oral aspirin enteric soluble tablets 150-300mg/d as early as possible after the onset of the disease, which can be changed to a prophylactic dose (50-325mg/d) after the acute phase. For those who cannot tolerate For those who cannot tolerate aspirin, clopidogrel can be used.
Study: NCT02638129
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone HCl/bupropion HCl placebo-matching tablets
Study: NCT04950790
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterilized water for injection，5ml/ injection, intravenous infusion, 20ml each time, once a day, diluted 250ml with normal saline, 15-30 drops/min.
Study: NCT00156975
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01876719
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02153697
Drug: Pigmanorm Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solar lentigines on the left back of the hand side are treated once a day during 7 weeks with Pigmanorm cream, a bleaching cream containing hydrochinon.
Study: NCT03159845
Drug: Zinc Sulfate Oral Product
Normalized name: zinc sulfate Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01100372
Drug: liposome-encapsulated doxorubicin citrate
Normalized name: liposomal encapsulated paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01601821
Drug: CsA+Rapamune+CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: Rapamune will be given as a loading dose of 6 mg once followed by maintenance dose of 2 mg to achieve a target trough level of 8-15 ng/ml. Part 2: Rapamune dose will be adjusted to achieve a target trough level of 10-15ng/ml through 6 months
Study: NCT01601821
Drug: CsA+MMF+CS
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control arm is the standard local practice (official protocol) in Iran:~Cyclosporine + MMF + Corticosteroid. The time period is from pre-study screening / baseline evaluation up to 12 months for patients who are maintained on CsA + MMF + CS.
Study: NCT00266136
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: see protocol
Study: NCT01468025
Drug: Active Theramine and Active Naproxen
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of Theramine and Naproxen, CoPack Kit Theraproxen
Study: NCT01468025
Drug: Naproxen and Theramine-like placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen co-administered with Theramine-like placebo.
Study: NCT02498418
Drug: Xifaxan®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, brand product.
Study: NCT02498418
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets in the same image of the generic rifaximin. Has no active ingredient.
Study: NCT02038803
Drug: TOBIpodhaler
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03386357
Drug: B (pembrolizumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200mg absolute, q3w)
Study: NCT03970304
Drug: Vivotif Typhoid Oral Vaccine
Normalized name: Vivotif Typhoid Oral Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
Study: NCT01492101
Drug: NKTR-102
Approvals — FDA: no, EMA: no, PMDA: no
Description: 145 mg/m2 NKTR-102 will be delivered q21day as a 90-minute intravenous (IV) infusion on day 1 of each treatment cycle.
Study: NCT00577005
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01004432
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will continue taking their current Methotrexate (MTX) treatment regimen.
Study: NCT01046357
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT01652625
Drug: Placebo toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: One gram of the placebo toothpaste was used twice daily by the control group patients. Except for the active Yunnan Baiyao extract, all ingredients contained in the placebo-toothpaste were the same as that in the experimental toothpaste.
Study: NCT00629161
Drug: Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant)
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months period of Traditional Chinese Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
Study: NCT00629161
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months period of placebo plus 1 month period without placebo
Study: NCT00577096
Drug: Total Therapy II
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Induction chemotherapy care included: vincristine, doxorubicin, and dexamethasone (VAD) (0.5 mg, 10 mg/m2, and 40 mg, respectively);dexamethasone, cyclophosphamide,etoposide, and cisplatin (DCEP) (40 mg, 400 mg/m2, 40 mg/m2, and 15 mg/m2,respectively); and cyclophosphamide,doxorubicin, and dexamethasone (CAD) (750 mg/m2, 15 mg/m2, and 40 mg, respectively) for mobilization.
Study: NCT00577096
Drug: Heparin, Low-Molecular-Weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who received thalidomide also received prophylactic low molecular weight heparin
Study: NCT02411318
Drug: ProLab 200mg caffeine capsule
Normalized name: caffeine 200 MG
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will swallow one ProLab caffeine 200mg tablet.
Study: NCT02411318
Drug: Glucose Tolerance Drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will consume 100 grams of glucose
Study: NCT00034918
Drug: ZD6474
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02696434
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily dosing
Study: NCT00832650
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: OD for 14 days
Study: NCT00658177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo